TY - JOUR
T1 - The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study)
T2 - an open-label randomised comparison
AU - Sherman, David G
AU - Albers, Gregory W
AU - Bladin, Christopher
AU - Fieschi, Cesare
AU - Gabbai, Alberto
AU - Kase, Carlos S
AU - O'Riordan, William
AU - Pineo, Graham
AU - on behalf of the PREVAIL Investigators
PY - 2007
Y1 - 2007
N2 - BACKGROUND: Venous thromboembolism prophylaxis with low molecular weight heparin or unfractionated heparin is recommended in acute ischaemic stroke, but which regimen provides optimum treatment is uncertain. We aimed to compare the efficacy and safety of enoxaparin with that of unfractionated heparin for patients with stroke. METHODS: 1762 patients with acute ischaemic stroke who were unable to walk unassisted were randomly assigned within 48 h of symptoms to receive either enoxaparin 40 mg subcutaneously once daily or unfractionated heparin 5000 U subcutaneously every 12 h for 10 days (range 6-14). Patients were stratified by National Institutes of Health Stroke Scale (NIHSS) score (severe stroke > or =14, less severe stroke
AB - BACKGROUND: Venous thromboembolism prophylaxis with low molecular weight heparin or unfractionated heparin is recommended in acute ischaemic stroke, but which regimen provides optimum treatment is uncertain. We aimed to compare the efficacy and safety of enoxaparin with that of unfractionated heparin for patients with stroke. METHODS: 1762 patients with acute ischaemic stroke who were unable to walk unassisted were randomly assigned within 48 h of symptoms to receive either enoxaparin 40 mg subcutaneously once daily or unfractionated heparin 5000 U subcutaneously every 12 h for 10 days (range 6-14). Patients were stratified by National Institutes of Health Stroke Scale (NIHSS) score (severe stroke > or =14, less severe stroke
UR - https://www.sciencedirect.com/science/article/pii/S0140673607606333
U2 - 10.1016/S0140-6736(07)60633-3
DO - 10.1016/S0140-6736(07)60633-3
M3 - Article
SN - 0140-6736
VL - 369
SP - 1347
EP - 1355
JO - The Lancet
JF - The Lancet
IS - 9570
ER -